ZOETIS (ZTS) Earnings Date & Reports

Key Takeaways

• Zoetis is scheduled to report second quarter 2026 results on Thursday, August 6, before the market opens. A conference call with CEO Kristin Peck and CFO Wetteny Joseph will follow at 8:30 a.m. ET.
• Wall Street expects adjusted earnings per share (EPS) of approximately $1.81 to $1.85, representing year-over-year growth of roughly 3% to 5% compared to $1.76 in Q2 2025.
• Consensus revenue estimates hover around $2.49 billion to $2.50 billion, implying modest year-over-year growth of approximately 1.3% to 1.4%.
• The report follows a challenging Q1 2026, when Zoetis missed both EPS and revenue expectations and lowered its full-year guidance, triggering a 21.5% single-day stock decline.
• U.S. companion animal demand remains the central concern, after CEO Kristin Peck cited increased price sensitivity among pet owners and declining veterinary visits last quarter.
• International and livestock segments have shown resilience, providing a partial offset to domestic headwinds and a key area of focus for investors this quarter.

Earnings Context and Why It Matters

Zoetis enters its Q2 2026 earnings report under intense scrutiny. The world's largest animal health company saw its stock lose more than half its value over the past 52 weeks, tumbling from a high of roughly $160 to the mid-$70s, following multiple quarters of decelerating growth and a particularly painful Q1 2026 miss. In May, management pointed to a more challenging operating environment than anticipated, with U.S. pet owners pulling back on veterinary spending. The company revised its full-year 2026 adjusted EPS guidance to $6.85–$7.00, down from $7.00–$7.10, and widened its revenue guidance range to $9.68 billion–$9.96 billion. This upcoming report will test whether those revised expectations are realistic — or whether conditions have deteriorated further.

Earnings Expectations

Analyst consensus for Zoetis's second quarter of fiscal 2026 points to adjusted EPS in the range of $1.81 to $1.85, with revenue between $2.49 billion and $2.50 billion. At the midpoint, that would represent roughly 5% EPS growth and less than 2% top-line expansion from the year-ago period, when Zoetis reported adjusted EPS of $1.76 on revenue of approximately $2.46 billion.

Notably, estimate revision momentum has been tepid. The Zacks Consensus Estimate has been essentially flat over the past 30 days, while the Most Accurate Estimate — a metric that reflects more recent analyst revisions — sits slightly below the consensus, yielding a negative Earnings ESP (Expected Surprise Prediction) of -0.75%. Combined with a Zacks Rank of #4 (Sell), the quantitative setup does not strongly favor an earnings beat, though the company has exceeded consensus in three of its last four quarters.

Key metrics investors will watch include U.S. companion animal product sales (which fell 11% in Q1), growth in the dermatology and parasiticide portfolios — including the flagship Simparica franchise — and performance in the livestock segment, which delivered 12% global growth in the prior quarter. Diagnostics revenue and international expansion, particularly in emerging markets, will also be closely monitored as potential bright spots.

AI Screener

As earnings season unfolds, investors looking to identify opportunities beyond a single stock may find value in Tickeron's AI Screener. This AI-powered stock and ETF discovery tool enables traders and investors to filter thousands of securities using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven signals. Whether searching for breakout candidates, trending sectors, or fundamentally screened ideas, the AI Screener helps narrow the field more efficiently than manual scanning. For those seeking to complement their earnings-season research with data-driven market insights, the AI Screener offers a practical starting point.

Market Reaction and Investor Sentiment

Sentiment around Zoetis heading into Q2 earnings remains cautious. The stock is trading near its 52-week low of $71.47, with the 200-day simple moving average sitting above $100 — underscoring the magnitude of the repricing that has occurred. Wall Street analysts have slashed price targets in recent months: UBS cut its target from $99 to $85, Stifel moved from $95 to $85, and JPMorgan lowered its target from $190 to $130 while maintaining an Overweight rating. The consensus analyst rating sits at "Hold," with an average price target near $118, implying significant potential upside — but only if the company can demonstrate stabilization.

Options activity has been elevated, with call volume surging nearly 60% above normal daily levels in late July, suggesting some traders are positioning for a positive surprise. However, the broader risk environment includes ongoing class action litigation related to the Q1 guidance cut and persistent uncertainty around U.S. consumer spending on pet care. A second consecutive miss on either the top or bottom line would likely intensify concerns about structural demand shifts in the companion animal market.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, investors will focus intently on any updates to Zoetis's full-year 2026 guidance. The current outlook — calling for organic operational revenue growth of 2% to 5% and adjusted net income growth of 2% to 6% — already reflects a more conservative stance than the original January guidance. Management commentary on the earnings call will be critical in assessing whether these targets remain achievable or face additional downside risk.

One area of particular interest is the cost and productivity program management launched following Q1 results. The program aims to tighten discretionary spending, improve procurement and operating efficiencies, and deliver a leveraged P&L (profit and loss statement) for the remainder of 2026. Progress on these initiatives could provide a margin cushion even if revenue growth remains subdued.

On the product side, Zoetis continues to invest in its pipeline, which includes 12 potential blockbuster candidates representing over $7 billion in additional market opportunity. The recently announced acquisition of Neogen's animal genomics business signals a commitment to expanding in livestock genetics, a complementary growth avenue. Meanwhile, the companion animal diagnostics segment — which grew 10% in Q1 — may offer a more resilient revenue stream tied to non-discretionary veterinary care.

Investors should also monitor competitive dynamics, particularly in the U.S. dermatology and parasiticide markets where generic incursions and pricing pressure have intensified. Any indication that market share is stabilizing or that veterinary visit trends are improving would be received positively. Conversely, signs that price sensitivity among pet owners is deepening could call the full-year outlook into question once again.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations